# Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP)

> **NCT07063199** · PHASE2 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 30 (estimated)

## Conditions studied

- Immune Thrombocytopenia
- Treatment

## Interventions

- **DRUG:** Daratumumab Injection

## Key facts

- **NCT ID:** NCT07063199
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08
- **Primary completion:** 2026-08
- **Final completion:** 2026-08
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07063199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07063199, "Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT07063199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*